Kroon S, Petersen C S, Andersen L P, Rasmussen L P, Vestergaard B F
Department of Dermato- Venereology, Bispebjerg Hospital, Copenhagen.
Dan Med Bull. 1989 Jun;36(3):298-300.
A randomised, double-blind, placebo-controlled cross-over study was conducted in 24 patients, nine females and 15 males, with a history of more than eight recurrences of genital herpes in the past year. The patients received a first treatment course with 400 mg acyclovir or matching placebo by mouth, twice daily, for 12 weeks. After cross-over patients received alternative medication for another 12 weeks. The patients were followed without treatment for a further three-month period. During acyclovir therapy, recurrences were completely prevented in 17 patients (71%) and the remaining seven patients had nine recurrences as compared to 18 recurrences while receiving placebo. The placebo treatment did not reduce the recurrence rate. No adverse effects were attributable to the acyclovir treatment period. All virus isolates tested after treatment remained sensitive to acyclovir. Acyclovir prophylaxis of recurrent genital herpes is effective and safe. A continuous suppressive therapy with acyclovir offers a basis for a normal sexual life to those patients severely incapacitated by their disease, but once medication is stopped, patients shed virus as before suppression.
对24例患者（9例女性，15例男性）进行了一项随机、双盲、安慰剂对照的交叉研究，这些患者在过去一年中生殖器疱疹复发超过8次。患者接受第一个疗程的治疗，口服400mg阿昔洛韦或匹配的安慰剂，每日两次，共12周。交叉后，患者接受替代药物治疗另外12周。患者在未接受治疗的情况下再随访三个月。在阿昔洛韦治疗期间，17例患者（71%）的复发被完全预防，其余7例患者有9次复发，而接受安慰剂时为18次复发。安慰剂治疗未降低复发率。阿昔洛韦治疗期间未出现不良反应。治疗后检测的所有病毒分离株对阿昔洛韦仍敏感。阿昔洛韦预防复发性生殖器疱疹有效且安全。对因疾病严重丧失能力的患者，持续使用阿昔洛韦进行抑制治疗为其正常性生活提供了基础，但一旦停药，患者就会像抑制治疗前一样排出病毒。
